Brief: Bioinvent Announces Strategic Changes In Portfolio
26/08/2025 07:31
Aug 26 (Reuters) - BioInvent International AB BINV.ST: BIOINVENT ANNOUNCES STRATEGIC CHANGES IN PORTFOLIO TO ACCELERATE LEAD CLINICAL PROGRAMS AND ENHANCE VALUE CREATION PHASE 2A STUDY OF BI-1206 IN COMBINATION WITH PEMBROLIZUMAB IN FIRST-LINE NSCLC TO INITIATE IN H2 2025 FOCUSING ON LEAD PROGRAMS BI-1206 AND BI-1808, WITH STRONG CLINICAL DATA AND UPCOMING VALUE-CREATION MILESTONES WILL PAUSE DEVELOPMENT OF PHASE 1 PROGRAMS FOR BI-1910 AND BI-1607 EXPECTS ITS CURRENT CASH RESOURCES TO FUND OPERATIONS INTO Q1 2027, BEYOND MULTIPLE KEY CLINICAL DATA READOUTS Source text: ID:nMFNbSgnrW Further company coverage: BINV.ST (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))